BATE KENNETH

SEC source: 0000905148-26-000312 · form4.xml · derivative · entry 5

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,550 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000312 · form4.xml · derivative · entry 4

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,100 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000312 · form4.xml · derivative · entry 3

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,100 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000312 · form4.xml · derivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,333 shares

Expires not disclosed

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

SEC source: 0000905148-26-000312 · form4.xml · derivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,666 shares

Expires not disclosed

F1 · derivative.exercise_price: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

F1 · shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

F2 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.exercise_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F2 · derivative.expiration_date: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.

F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · derivative · entry 17

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · derivative · entry 16

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2028-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · derivative · entry 15

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,470 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 14

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $490.7625 to $491.42, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 13

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,657

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $489.74 to $490.7125, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 12

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,590

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $488.74 to $489.49, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 11

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,286

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.13 to $488.09, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 10

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,061

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.10 to $486.99, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 9

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,888

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.10 to $486.04, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 8

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,896

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.02 to $485.015, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 7

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,827

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.00 to $483.92, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 6

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,896

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.84 to $482.71, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 5

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,180

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.71 to $481.68, inclusive.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 4

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,439

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.66 to $480.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 3

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,202

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-050668 · wk-form4_1762550418.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,097

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · derivative · entry 8

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2027-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 7

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.13 to $368.98, inclusive.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 6

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,523

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.115 to $368.05, inclusive.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 5

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,627

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.22, inclusive.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 4

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,227

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.91 to $365.77, inclusive.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 3

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,794

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.88 to $364.87, inclusive.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,310

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.87 to $363.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

SEC source: 0001210238-25-000005 · wk-form4_1755295493.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,627

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-032863 · wk-form4_1750797916.xml · derivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,290

Underlying: Common Stock · 1,290 shares

Expires 2035-06-20

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date.

SEC source: 0001628280-25-032863 · wk-form4_1750797916.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,627

F1 · kind: Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001104659-25-059042 · tm2517800-7_4seq1.xml · derivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,550

Underlying: Common Stock · 26,550 shares

Expires 2035-06-10

F1 · derivative.exercise_date: This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · derivative · entry 15

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,470

Underlying: Common Stock · 4,530 shares

Expires 2026-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · derivative · entry 14

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,470 shares

Expires 2025-06-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · derivative · entry 13

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2025-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 12

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,912

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.99 to $360.17, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 11

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,128

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.94 to $359.84, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 10

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,152

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.91 to $358.83, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 9

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,700

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.83 to $357.79, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 8

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,738

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.83 to $356.79, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 7

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,529

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.79 to $355.78, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 6

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,074

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.78 to $354.50, inclusive.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 5

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,312

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 4

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,812

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.98 to $351.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 3

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,382

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-25-009076 · wk-form4_1740778208.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,912

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-078754 · ownership.xml · derivative · entry 2

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,105

Underlying: Common Stock · 1,105 shares

Expires 2031-06-25

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.

SEC source: 0000950170-24-078754 · ownership.xml · nonDerivative · entry 1

BATE KENNETH · CIK 0001210238 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,912

F1 · shares: Represents a grant of restricted stock units, which vest on June 25, 2025, provided the Reporting Person continues in service with the Issuer on such date.